Thursday, 22 March 2018 16:19

In Memoriam: Dan Stinchcomb

Dan Stinchcomb, PhD, Chief Scientific Officer for IDRI (Infectious Disease Research Institute) a Seattle-based global health nonprofit biotech, passed away Feb. 21, 2018, after a brief illness. Stinchcomb joined IDRI in 2016 as a Senior Vice President and was promoted to the CSO role in 2017. He made a tremendous impact on IDRI’s work with his deep expertise in the field of viral diseases and passion for finding new solutions for those diseases. Stinchcomb is well known for his expertise in flaviviruses and influenza, having developed a vaccine against Dengue and leading projects at IDRI to develop novel RNA-based vaccines.

 

Stinchcomb received his PhD from Stanford University and his BA from Harvard University. His prolific career in life sciences began with assistant and associate professor roles at Harvard, later moving into senior scientific leadership positions at Synergen Inc. and Ribozyme Pharmaceuticals Inc., where he served as Director of Biology Research. He then moved into the field of veterinary products at Heska Corp., where he led all aspects of product research and development. In 2005, Stinchcomb co-founded and served as President and CEO of Inviragen Inc., which he transformed from a virtual start-up to a global clinical state company with sites in Colorado, Wisconsin and Singapore and translated two vaccines from the research to clinical trials. Stinchcomb authored more than 50 scientific publications, was an inventor on more than 30 patents and served on various boards and committees. He was a member of ASM for many years.

 

Submitted By:

 

Lee Schoentrup

Director, Communications

IDRI (Infectious Disease Research Institute)

Seattle, WA

TPL_asm2013_SEARCH

7175:in-memoriam-dan-stinchcomb